This clinical trial is focused on studying a rare condition called Fibrodysplasia Ossificans Progressiva (FOP). FOP is a disorder where soft tissues in the body, like muscles and tendons, gradually turn into bone, leading to restricted movement. The study is testing a new treatment called fidrisertib, also known by its code name IPN60130. This treatment is being compared to a placebo to see if it can help reduce the formation of new bone in people with FOP.

The purpose of the study is to evaluate how effective and safe fidrisertib is for both children and adults with FOP. Participants in the study will take the medication in the form of a hard capsule by mouth. The study will last for a period of up to 60 days, during which participants will be monitored for any changes in their condition and any side effects they might experience. The study will use imaging techniques like computed tomography (CT) to measure changes in bone formation.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their condition. The study aims to provide valuable information on whether fidrisertib can effectively slow down or stop the progression of FOP, offering hope for better management of this challenging condition. Participants will be closely monitored to ensure their safety and well-being during the trial.